The roles of bone-derived exosomes and exosomal microRNAs in regulating bone remodelling

Journal of Cellular and Molecular Medicine

Volumn 21, Issue 5, 2017, Pages 1033-1041

  Xie, Yong ^a   Chen, Yanyu ^b   Zhang, Licheng ^a   Ge, Wei ^b   Tang, Peifu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

bone remodelling; exosome; microRNA; osteoblast; osteoclast

Indexed keywords

5' NUCLEOTIDASE; BETA1 INTEGRIN; ENDOGLIN; EPHRIN A2; GROWTH FACTOR; HERMES ANTIGEN; MICRORNA; MICROSOMAL AMINOPEPTIDASE; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE;

BONE CELL; BONE GROWTH; BONE REMODELING; EXOSOME; HUMAN; MOLECULAR INTERACTION; NONHUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; PRIORITY JOURNAL; REVIEW; SKELETON; UBIQUITINATION; ANIMAL; BIOLOGICAL MODEL; BONE; METABOLISM;

ANIMALS; BONE AND BONES; BONE REMODELING; EXOSOMES; HUMANS; MICRORNAS; MODELS, BIOLOGICAL;

EID: 85005938329     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.13039     Document Type: Review

References (86)

1. Sucur A, Katavic V, Kelava T, et al. Induction of osteoclast progenitors in inflammatory conditions: key to bone destruction in arthritis. Int Orthop. 2014; 38: 1893–903.
2. Kowada T, Kikuta J, Kubo A, et al. In vivo fluorescence imaging of bone-resorbing osteoclasts. J Am Chem Soc. 2011; 133: 17772–6.
3. Liu W, Yang LH, Kong XC, et al. Meta analysis of osteoporosis: fracture risks, medication and treatment. Minerva Med. 2015; 106: 203–14.
4. Manolagas SC. Steroids and osteoporosis: the quest for mechanisms. J Clin Invest. 2013; 123: 1919–21.
5. Henriksen K, Karsdal MA, Martin TJ. Osteoclast-derived coupling factors in bone remodeling. Calcif Tissue Int. 2014; 94: 88–97.
6. Miyazaki T, Tokimura F, Tanaka S. A review of denosumab for the treatment of osteoporosis. Patient Prefer Adherence. 2014; 8: 463–71.
7. Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys. 2008; 473: 201–9.
8. Xing L, Schwarz EM, Boyce BF. Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev. 2005; 208: 19–29.
9. Kikuta J, Ishii M. Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases. Rheumatology (Oxford, England). 2013; 52: 226–34.
10. Frost HM. The pathomechanics of osteoporoses. Clin Orthop Relat Res. 1985; 200: 198–225.
11. Sanchez-Duffhues G, Hiepen C, Knaus P, et al. Bone morphogenetic protein signaling in bone homeostasis. Bone. 2015; 80: 43–59.
12. Alford AI, Kozloff KM, Hankenson KD. Extracellular matrix networks in bone remodeling. Int J Biochem Cell Biol. 2015; 65: 20–31.
13. Chambers TJ. The birth of the osteoclast. Ann N Y Acad Sci. 2010; 1192: 19–26.
14. Nakashima T, Hayashi M, Takayanagi H. New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab. 2012; 23: 582–90.
15. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone. 2007; 40: 251–64.
16. Boyce BF. Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res. 2013; 92: 860–7.
17. Javed A, Chen H, Ghori FY. Genetic and transcriptional control of bone formation. Oral Maxillofac Surg Clin North Am. 2010; 22: 283–93.
18. Sims NA, Walsh NC. Intercellular cross-talk among bone cells: new factors and pathways. Current Osteoporos Rep. 2012; 10: 109–17.
19. Chiu YG, Ritchlin CT. DC-STAMP: a key regulator in osteoclast differentiation. J Cell Physiol. 2016; 231: 2402–7.
20. Huynh N, VonMoss L, Smith D, et al. Characterization of regulatory extracellular vesicles from osteoclasts. J Dent Res. 2016; 95: 673–9.
21. van der Eerden BC. MicroRNAs in the skeleton: cell-restricted or potent intercellular communicators? Arch Biochem Biophys. 2014; 561: 46–55.
22. Deng L, Wang Y, Peng Y, et al. Osteoblast-derived microvesicles: a novel mechanism for communication between osteoblasts and osteoclasts. Bone. 2015; 79: 37–42.
23. Soekmadji C, Russell PJ, Nelson CC. Exosomes in prostate cancer: putting together the pieces of a puzzle. Cancers. 2013; 5: 1522–44.
24. Choi DS, Yang JS, Choi EJ, et al. The protein interaction network of extracellular vesicles derived from human colorectal cancer cells. J Proteome Res. 2012; 11: 1144–51.
25. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014; 30: 255–89.
26. Bobrie A, Thery C. Exosomes and communication between tumours and the immune system: are all exosomes equal? Biochem Soc Trans. 2013; 41: 263–7.
27. Hong BS, Cho JH, Kim H, et al. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genom. 2009; 10: 556.
28. DiGirolamo DJ, Clemens TL, Kousteni S. The skeleton as an endocrine organ. Nat Rev Rheumatol. 2012; 8: 674–83.
29. Prideaux M, Findlay DM, Atkins GJ. Osteocytes: the master cells in bone remodelling. Curr Opin Pharmacol. 2016; 28: 24–30.
30. Pi M, Quarles LD. Novel bone endocrine networks integrating mineral and energy metabolism. Current Osteoporos Rep. 2013; 11: 391–9.
31. Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol. 2011; 6: 121–45.
32. Sun W, Zhao C, Li Y, et al. Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity. Cell discov. 2016; 2: 16015.
33. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013; 200: 373–83.
34. Runz S, Keller S, Rupp C, et al. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol. 2007; 107: 563–71.
35. Pols MS, Klumperman J. Trafficking and function of the tetraspanin CD63. Exp Cell Res. 2009; 315: 1584–92.
36. Antonyak MA, Li B, Boroughs LK, et al. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci USA. 2011; 108: 4852–7.
37. Ge M, Ke R, Cai T, et al. Identification and proteomic analysis of osteoblast-derived exosomes. Biochem Biophys Res Commun. 2015; 467: 27–32.
38. Lai RC, Yeo RW, Padmanabhan J, et al. Isolation and characterization of exosome from human embryonic stem cell-derived C-Myc-immortalized mesenchymal stem cells. Methods Mol Biol. 2016; 1416: 477–94.
39. Yang X, Matsuda K, Bialek P, et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell. 2004; 117: 387–98.
40. Xu JF, Yang GH, Pan XH, et al. Altered microRNA expression profile in exosomes during osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. PLoS One. 2014; 9: e114627.
41. Cui Y, Luan J, Li H, et al. Exosomes derived from mineralizing osteoblasts promote ST2 cell osteogenic differentiation by alteration of microRNA expression. FEBS Lett. 2016; 590: 185–92.
42. Qin Y, Sun R, Wu C, et al. Exosome: a novel approach to stimulate bone regeneration through regulation of osteogenesis and angiogenesis. Int J Mol Sci. 2016; 17: 712.
43. Qin Y, Wang L, Gao Z, et al. Bone marrow stromal/stem cell-derived extracellular vesicles regulate osteoblast activity and differentiation in vitro and promote bone regeneration in vivo. Sci Rep. 2016; 6: 21961.
44. Zhao L, Jiang S, Hantash BM. Transforming growth factor beta1 induces osteogenic differentiation of murine bone marrow stromal cells. Tissue Eng Part A. 2010; 16: 725–33.
45. Luther G, Wagner ER, Zhu G, et al. BMP-9 induced osteogenic differentiation of mesenchymal stem cells: molecular mechanism and therapeutic potential. Curr Gene Ther. 2011; 11: 229–40.
46. Lamplot JD, Qin J, Nan G, et al. BMP9 signaling in stem cell differentiation and osteogenesis. Am J Stem Cells. 2013; 2: 1–21.
47. Narayanan R, Huang CC, Ravindran S. Hijacking the cellular mail: exosome mediated differentiation of mesenchymal stem cells. Stem Cells Int. 2016; 2016: 3808674.
48. Solberg LB, Stang E, Brorson SH, et al. Tartrate-resistant acid phosphatase (TRAP) co-localizes with receptor activator of NF-KB ligand (RANKL) and osteoprotegerin (OPG) in lysosomal-associated membrane protein 1 (LAMP1)-positive vesicles in rat osteoblasts and osteocytes. Histochem Cell Biol. 2015; 143: 195–207.
49. Ekstrom K, Omar O, Graneli C, et al. Monocyte exosomes stimulate the osteogenic gene expression of mesenchymal stem cells. PLoS One. 2013; 8: e75227.
50. Omar OM, Graneli C, Ekstrom K, et al. The stimulation of an osteogenic response by classical monocyte activation. Biomaterials. 2011; 32: 8190–204.
51. Li D, Liu J, Guo B, et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat Commun. 2016; 7: 10872.
52. Xiao Z, Blonder J, Zhou M, et al. Proteomic analysis of extracellular matrix and vesicles. J Proteomics. 2009; 72: 34–45.
53. Shapiro IM, Landis WJ, Risbud MV. Matrix vesicles: are they anchored exosomes? Bone. 2015; 79: 29–36.
54. Nakamachi Y, Kawano S, Takenokuchi M, et al. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 2009; 60: 1294–304.
55. Hammond SM. Dicing and slicing: the core machinery of the RNA interference pathway. FEBS Lett. 2005; 579: 5822–9.
56. Hutvagner G. Small RNA asymmetry in RNAi: function in RISC assembly and gene regulation. FEBS Lett. 2005; 579: 5850–7.
57. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev. 2004; 18: 504–11.
58. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6: 259–69.
59. Weilner S, Schraml E, Redl H, et al. Secretion of microvesicular miRNAs in cellular and organismal aging. Exp Gerontol. 2013; 48: 626–33.
60. Egea V, Zahler S, Rieth N, et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/beta-catenin signaling. Proc Natl Acad Sci USA. 2012; 109: E309–16.
61. Wei J, Li H, Wang S, et al. let-7 enhances osteogenesis and bone formation while repressing adipogenesis of human stromal/mesenchymal stem cells by regulating HMGA2. Stem Cells Dev. 2014; 23: 1452–63.
62. Zhang Y, Xie RL, Croce CM, et al. A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2. Proc Natl Acad Sci USA. 2011; 108: 9863–8.
63. Li Z, Hassan MQ, Volinia S, et al. A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proc Natl Acad Sci USA. 2008; 105: 13906–11.
64. Huang J, Zhao L, Xing L, et al. MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation. Stem Cells. 2010; 28: 357–64.
65. Lauvrak SU, Munthe E, Kresse SH, et al. Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes. Br J Cancer. 2013; 109: 2228–36.
66. Schaap-Oziemlak AM, Raymakers RA, Bergevoet SM, et al. MicroRNA hsa-miR-135b regulates mineralization in osteogenic differentiation of human unrestricted somatic stem cells. Stem Cells Dev. 2010; 19: 877–85.
67. Xu S, Cecilia Santini G, De Veirman K, et al. Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients. PLoS One. 2013; 8: e79752.
68. Nemoto E, Ebe Y, Kanaya S, et al. Wnt5a signaling is a substantial constituent in bone morphogenetic protein-2-mediated osteoblastogenesis. Biochem Biophys Res Commun. 2012; 422: 627–32.
69. Hwang S, Park SK, Lee HY, et al. miR-140-5p suppresses BMP2-mediated osteogenesis in undifferentiated human mesenchymal stem cells. FEBS Lett. 2014; 588: 2957–63.
70. Hassan MQ, Maeda Y, Taipaleenmaki H, et al. miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J Biol Chem. 2012; 287: 42084–92.
71. Kim YJ, Bae SW, Yu SS, et al. miR-196a regulates proliferation and osteogenic differentiation in mesenchymal stem cells derived from human adipose tissue. J Bone Miner Res. 2009; 24: 816–25.
72. Bhushan R, Grunhagen J, Becker J, et al. miR-181a promotes osteoblastic differentiation through repression of TGF-beta signaling molecules. Int J Biochem Cell Biol. 2013; 45: 696–705.
73. Zhang J, Tu Q, Bonewald LF, et al. Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1. J Bone Miner Res. 2011; 26: 1953–63.
74. You L, Gu W, Chen L, et al. MiR-378 overexpression attenuates high glucose-suppressed osteogenic differentiation through targeting CASP3 and activating PI3K/Akt signaling pathway. Int J Clin Exp Pathol. 2014; 7: 7249–61.
75. Chen C, Cheng P, Xie H, et al. MiR-503 regulates osteoclastogenesis via targeting RANK. J Bone Miner Res. 2014; 29: 338–47.
76. James AW. Review of Signaling Pathways Governing MSC Osteogenic and Adipogenic Differentiation. Scientifica (Cairo). 2013; 2013: 684736.
77. Cheng P, Chen C, He HB, et al. miR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene homolog B. J Bone Miner Res. 2013; 28: 1180–90.
78. Wang X, Guo B, Li Q, et al. miR-214 targets ATF4 to inhibit bone formation. Nat Med. 2013; 19: 93–100.
79. Zhao C, Sun W, Zhang P, et al. miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway. RNA Biol. 2015; 12: 343–53.
80. Kobayashi Y, Uehara S, Udagawa N, et al. Regulation of bone metabolism by Wnt signals. J Biochem. 2016; 159: 387–92.
81. Matsuo K. Cross-talk among bone cells. Curr Opin Nephrol Hypertens. 2009; 18: 292–7.
82. Silva M, Melo SA. Non-coding RNAs in Exosomes: new Players in Cancer Biology. Curr Genomics. 2015; 16: 295–303.
83. Inder KL, Ruelcke JE, Petelin L, et al. Cavin-1/PTRF alters prostate cancer cell-derived extracellular vesicle content and internalization to attenuate extracellular vesicle-mediated osteoclastogenesis and osteoblast proliferation. J Extracell Vesicles. 2014; 3: 23784.
84. Raimondi L, De Luca A, Amodio N, et al. Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation. Oncotarget. 2015; 6: 13772–89.
85. Trokovic N, Pollanen R, Porola P, et al. Exosomal secretion of death bullets: a new way of apoptotic escape? Am J Physiol Endocrinol Metab. 2012; 303: E1015–24.
86. Ohno S, Kuroda M. Exosome-Mediated Targeted Delivery of miRNAs. Methods Mol Biol. 2016; 1448: 261–70.